We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...

Eli Lilly has followed Novo Nordisk in announcing ... supporting products like GLP-1 agonist Trulicity (dulaglutide) and dual GIP/GLP-1 agonist Mounjaro (tirzepatide) for diabetes, as well as ...

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Eli Lilly's Current ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...

Declining sales of Trulicity, rising pricing pressure on ... (You can read the full research report on Eli Lilly here >>>) Shares of S&P Global have outperformed the Zacks Business - Information ...

Eli Lilly and Company discovers ... Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux ...

Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014). Since the beginning of the year, one insider made 24 sales of Eli Lilly and Company (NYSE:LLY) shares.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...